Akslen´s team, and now CCBIO, are engaged in translational cancer research with a strong focus on exploration and validation of novel biomarkers for more biologically based classification and grading of malignant tumors, as a better guide for targeted treatment. The group has included projects on various cancers, such as breast cancer, malignant melanoma, prostate cancer, and gynecologic cancers. Studies of human tumor samples are combined with experimental cell and animal models to improve translation. The overall aim is to provide novel biomarkers which can assist in prediction of aggressive tumor behavior and be helpful in tailored treatment.